DDInter1607 DDInter1802
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ticagrelor
Ritonavir {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Ticagrelor
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ritonavir {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ritonavir {u} (Compound) causes {v} (Side Effect) Rectal haemorrhage
Rectal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Ritonavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ticagrelor (Compound)
Ritonavir (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Ticagrelor
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ritonavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ritonavir (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ritonavir (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ritonavir (Compound) causes Rectal haemorrhage (Side Effect) and Rectal haemorrhage (Side Effect) is caused by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)